Pulmatrix
Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.
- 24
- Public company
- Framingham, MA, USUnited States
Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.
pulmatrix.comCrawled Oct 15, 2026
With iSPERSE technology, PULMATRiX is expanding therapeutic care for patients with serious disease through a new generation of PULMONARY-DELIVERED THERAPEUTICS.
Pulmatrix reports its second-quarter 2026 financial performance and updates on its planned merger. The biopharmaceutical company specializes in inhaled therapeutics for migraine and respiratory diseases using its proprietary **iSPERSE™** technology. Key updates include progress toward closing the merger and continued development of treatments addressing unmet medical needs.
Aug 2026nasdaq.comNews article
Pulmatrix reports its first-quarter 2026 financial performance as a biopharmaceutical company specializing in inhaled therapies. The company continues advancing novel treatments targeting respiratory and pulmonary diseases. Pulmatrix operates under the Nasdaq listing **PULM**, reflecting its focus on inhaled drug development.
May 2026PR NewswireNews article
Pulmatrix closes a private placement of Series B Convertible Preferred Stock with Eos SENOLYTIX affiliate as part of its planned merger. The stock converts into common shares at $2.20 per share. The transaction advances Pulmatrix’s merger strategy with Eos.
Apr 2026Yahoo FinanceNews article
Pulmatrix Inc. merges with Eos SENOLYTIX to develop therapies targeting mitochondrial function and extending health span. Eos SENOLYTIX specializes in treatments designed to restore mitochondrial health, a key focus of the combined company. The merger follows Pulmatrix’s existing work in respiratory and pulmonary drug delivery. Stock prices for Pulmatrix have declined following the announcement.
Mar 2026RTTNewsNews article